BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
about
Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyComparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusCeftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.Microtiter plate-based assay for inhibitors of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleNovel agents for the treatment of resistant Gram-positive infections.Novel antibacterial agents for the treatment of serious Gram-positive infections.In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.PBP 2a mutations producing very-high-level resistance to beta-lactams.Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year ReviewQuality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelAnti-MRSA agents: under investigation, in the exploratory phase and clinically available.Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbitsResults of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsAntimicrobial therapy of Staphylococcus aureus bloodstream infection.Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
P2860
Q28235095-1DB23268-4C3E-40FC-AFF2-3FE627EBB661Q30369604-2C49335C-92D7-45F7-9A4E-180AE84AD5B6Q33559139-F6D81B9B-CDC0-446F-9C69-1CB239DB9EEDQ33935282-658677BF-D1E1-48DD-B4BD-D2F99687E3E5Q34433342-EBEF4223-48AD-426A-8A5C-8044A2EDB83CQ34624359-7599B176-AA4E-4AA8-B807-8D40E0655FACQ35005000-61978706-0E7A-4C24-854E-F56E52F9FCE2Q35026567-D94C6981-DB7C-4826-A39B-6CAED7C1685BQ35056042-D308D337-83AE-46E6-8026-7116D00AB373Q35073345-3EB8F4D8-A4C7-4C1D-A1B7-1C98017F0B1AQ35124610-8591F425-5CAC-42FD-B65C-A20E362AF426Q35191417-4625A3AA-D053-4D39-A82F-A7612E1061BAQ35547377-585A9DB8-1539-4A6A-8B37-63CB38B38245Q35588850-1BE4AC64-FCF5-4E1F-84CC-1BBA1F84B70AQ35715050-DBB605E6-A41C-4EFA-8DE1-BB19D45ED076Q35806369-E708698D-CEAC-4B57-8F4C-59D5C31667DFQ35879080-12F43676-9BD6-4678-BFDE-3C00755EDF1BQ35964560-EB9A57DD-1D16-42A8-BA46-29E7A963FED7Q36018587-27FF0F29-CAE5-49B4-BFBA-27C4928DBC4CQ36233502-503CABA2-9F7F-4456-83BE-8E878B216195Q36283731-E883BD46-FDED-4FF9-BC30-FF5C9A8C8F6DQ36396146-16152463-3C92-4EE5-A549-92AFD60A2671Q36422630-EAA3C743-8731-42EC-B6B7-5FA9FF8B965EQ36613912-A9F79B17-51A9-4E2B-9A4C-424497EE579DQ36763997-5216ACC4-01BC-4325-9C5C-0521B56EAC32Q36932924-F60EB74E-FBFF-4201-8DA8-2678B08F1A9EQ36968150-76BAD336-6888-4D8B-B13D-9B31F6429F26Q37119259-7B4DCBE4-1E48-4956-8AEA-6CF209AFB105Q37274751-3E851D00-C9D4-480D-9F5B-954E0643EF81Q37461413-E816F59F-3CA8-4509-BAB5-C07B704C1E2EQ37519733-3DB39EF9-FE41-434F-874B-702D116CD8A6Q37593094-31691D80-F590-44CA-B866-29008F7DEB85Q37598693-065941BD-64F7-4BA7-A993-ACF0F1D9AC65Q37733667-21E04E1D-E620-4A21-8E8B-BDAF4E143C62Q38797012-A39F2904-6041-499D-8500-15ADBBECFD3CQ38892614-F6C3ED22-A766-4AE8-BE0D-BBBBD9B1205FQ40600643-86D7B0B8-E79D-462D-A299-4E4A8ECF62E6Q40967997-B57ED51D-6995-4B8D-B49E-D0268F694485Q40968003-2678737C-DB4F-4257-99B6-07D76C3C3FDAQ41092910-CD3D57CA-75E4-4118-8FE9-714E013B26B7
P2860
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@en
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@nl
type
label
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@en
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@nl
prefLabel
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@en
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@nl
P2093
P2860
P1476
BAL9141, a novel extended-spec ...... of experimental endocarditis.
@en
P2093
I Heinze-Krauss
J M Entenza
M P Glauser
P Moreillon
P2860
P304
P356
10.1128/AAC.46.1.171-177.2002
P407
P577
2002-01-01T00:00:00Z